08 April
2024
Destiny Pharma plc
("Destiny Pharma" or "the
Company")
Notice of Full Year Results and Investor
Presentation
Brighton,
United Kingdom - Destiny Pharma plc (AIM:
DEST), a clinical stage innovative biotechnology company focused on
the development of novel medicines that can prevent life
threatening infections, will announce its financial results for the
year ended 31 December 2023, on Thursday 25 April 2024.
Chris Tovey, Chief Executive Officer, and Shaun
Claydon, Chief Financial Officer, will host a briefing for analysts
at 8.30am BST followed by a presentation to all existing and
potential shareholders at 11:00am BST held via the Investor Meet
Company platform. Further details for the analyst briefing will be
shared by invitation in due course.
Questions can be submitted pre-event via the
Investor Meet Company dashboard up until 09:00am BST the day before
the meeting, or at any time during the live
presentation.
Investors can sign up to Investor Meet Company
for free, and add to meet Destiny Pharma
plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc
on the Investor Meet Company platform will automatically be
invited.
For further
information, please contact:
Destiny Pharma
plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway / Michael
Trace
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital
(Nominated Advisor and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny
Pharma
Destiny Pharma is an innovative, clinical-stage
biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development
pipeline includes two late stage assets NTCD-M3, a microbiome-based
biotherapeutic for the prevention of C. difficile infection (CDI)
recurrence which is the leading cause of hospital acquired
infection in the US, and XF-73 nasal gel, a proprietary drug
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA.
For further information on the company, please
visit www.destinypharma.com
